Investor Relations

Charles River Associates Enhances Life Sciences Strategy Consulting Practice


New Colleagues Enhance CRA’s Life Sciences Practice and Expand Geographic Presence

BOSTON--(BUSINESS WIRE)--Jan. 4, 2018-- CRA International, Inc. (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced the arrival of several new colleagues to CRA’s Life Sciences Practice. These consultants will provide additional breadth and depth to CRA’s client offerings across the industry—enhancing CRA’s capabilities in pricing and market access and increasing CRA’s geographic presence in Europe.

“We are excited to welcome our new colleagues to CRA,” said Paul Maleh, CRA’s President and Chief Executive Officer. “As we continue to grow our portfolio, the expansion of our Life Sciences team enables CRA to serve a broader array of client needs and increases our geographic presence in Europe.” The addition of these new colleagues will grow the practice to over 180 consultants and provide a new office in Cambridge, United Kingdom.

“Our new colleagues provide even greater depth to our offerings, particularly strategic consulting to address our clients’ pricing and market access challenges,” added Greg Bell, Life Sciences Vice President and Practice Leader.

Among the consultants joining CRA from QuintilesIMS, now doing business as IQVIA, are seven vice presidents: Joanne Clark, Walter Colasante, Stephen Deitch, Pascale Diesel, Carla (Niven) Fisher, Eva Marchese, and Andras Ruppert.

Joanne Clark has extensive expertise in market access and solving strategic issues for pharmaceutical, biotech, and health care clients globally. She has worked with regional and global business units on brand and above brand consulting projects and has experience across a range of therapeutic areas.

Walter Colasante has experience in both the pharmaceutical and consulting industries in many therapeutic areas, most notably oncology, CNS, and rare diseases. He specializes in global market access strategies and EU parallel trade.

Stephen Deitch has 30 years of experience in senior roles in health care and life sciences as a consultant, payer, and pharmacist. He has led engagements on a variety of commercial issues and has worked across a full range of therapy areas, with a focus on metabolic disorders, rare diseases, oncology, and respiratory disease.

Pascale Diesel has 18 years of pharmaceutical and biotech experience in global development, marketing, planning, and business development. She specializes in decision optimization and commercial transactional support. She is an expert in product strategy and valuation, market and strategic assessment, product lifecycle, and portfolio management.

Carla (Niven) Fisher has 20 years of consulting expertise in pricing, market access, and strategy for the pharmaceutical industry. She has worked across many different clients and therapy areas. Her main areas of expertise are oncology, cardiovascular, diabetes, pain and multiple sclerosis.

Eva Marchese specializes in competitive strategy, pricing, market access, and research primarily in the pharmaceutical, biotech, and life sciences industries. Her consulting background is focused on advising pharmaceutical and medical device companies on global pricing and market access.

Andras Ruppert has more than 20 years of experience working with global pharmaceutical, biotech, and medical device industries to solve strategic issues. He is an expert in European health care systems, including their funding, evaluation, and reimbursement processes. He also helps Life Sciences companies to adjust internal structures and processes to the changing environment.

About CRA's Life Sciences Practice
The CRA Life Sciences Practice works with leading biotech, medical device, and pharmaceutical companies; law firms; regulatory agencies; and national and international industry associations. We provide the analytical expertise and industry experience needed to address our clients’ toughest issues. We have a reputation for rigorous and innovative analysis, careful attention to detail, and the ability to work effectively as part of a wider team of advisers.

About Charles River Associates (CRA)
Charles River Associates® is a global consulting firm specializing in economic, financial, and management consulting services. CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at Follow us on LinkedIn, Twitter, and Facebook.

Statements in this press release concerning the addition of Joanne Clark, Walter Colasante, Stephen Deitch, Pascale Diesel, Carla (Niven) Fisher, Eva Marchese, and Andras Ruppert, the Company’s life sciences consulting offering, and future business Joanne Clark, Walter Colasante, Stephen Deitch, Pascale Diesel, Carla (Niven) Fisher, Eva Marchese, and Andras Ruppert may generate for the Company and statements using the terms “provides,” “enhance,” “expects,” “strengthen,” or similar expressions are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors that could cause actual performance or results to differ materially from any forward-looking statements made by the Company include, among others, the failure to generate engagements for us; dependence on the growth of our litigation or strategy consulting practice, including in life sciences; the potential loss of clients; the demand environment; global economic conditions; foreign exchange rate fluctuations; and intense competition, as well as other potential factors that could affect our financial results are included in our periodic filings with the Securities and Exchange Commission, including those under the heading “Risk Factors.” We cannot guarantee any future results, levels of activity, performance, or achievement. We undertake no obligation to update any forward-looking statements after the date of this press release, and we do not intend to do so.

Source: CRA International, Inc.

Charles River Associates
Media Relations, 617-425-6453
Sharon Merrill Associates, Inc.
Andrew Blazier, 617-542-5300
Senior Associate